• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma.

作者信息

Al Hadidi Samer, Ababneh Obada, Schinke Carolina, Thanendrarajan Sharmilan, Bailey Clyde, Smith Robert, Panozzo Susan, Alapat Daisy, Tricot Guido, Shaughnessy John, Zhan Fenghuang, Sawyer Jeffrey, Siegel Eric R, Barlogie Bart, van Rhee Frits, Zangari Maurizio

机构信息

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR.

Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.

出版信息

Blood Adv. 2025 Feb 25;9(4):950-953. doi: 10.1182/bloodadvances.2024014889.

DOI:10.1182/bloodadvances.2024014889
PMID:39786380
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11934280/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38de/11934280/70719bff17ef/BLOODA_ADV-2024-014889-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38de/11934280/70719bff17ef/BLOODA_ADV-2024-014889-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38de/11934280/70719bff17ef/BLOODA_ADV-2024-014889-gr1.jpg

相似文献

1
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma.全疗法IV的长期随访：一项针对标危多发性骨髓瘤的3期临床试验。
Blood Adv. 2025 Feb 25;9(4):950-953. doi: 10.1182/bloodadvances.2024014889.
2
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.来那度胺联合地塞米松与观察治疗高危冒烟型多发性骨髓瘤患者（QuiRedex）：一项随机、对照、3 期临床试验的长期随访。
Lancet Oncol. 2016 Aug;17(8):1127-1136. doi: 10.1016/S1470-2045(16)30124-3. Epub 2016 Jul 9.
3
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗，随后进行达雷妥尤单抗维持或观察治疗，适用于适合移植的新诊断多发性骨髓瘤：CASSIOPEIA 随机对照 3 期试验的长期随访。
Lancet Oncol. 2024 Aug;25(8):1003-1014. doi: 10.1016/S1470-2045(24)00282-1. Epub 2024 Jun 15.
4
Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.沙利度胺在近期诊断的多发性骨髓瘤患者自体干细胞移植前后的应用（HOVON-50）：3期随机对照试验的长期结果
Lancet Haematol. 2018 Oct;5(10):e479-e492. doi: 10.1016/S2352-3026(18)30149-2.
5
Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial.多发性骨髓瘤患者自体-自体串联与自体-异体造血干细胞移植：血液与骨髓移植临床试验网络0102试验的长期随访结果
Biol Blood Marrow Transplant. 2020 Apr;26(4):798-804. doi: 10.1016/j.bbmt.2019.11.018. Epub 2019 Nov 19.
6
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial.抗GPRC5D嵌合抗原受体T细胞疗法作为抗BCMA嵌合抗原受体T细胞疗法后进展性多发性骨髓瘤患者的挽救治疗：一项单中心、单臂、2期试验
Lancet Haematol. 2025 May;12(5):e365-e375. doi: 10.1016/S2352-3026(25)00048-1. Epub 2025 Apr 12.
7
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.卡非佐米或硼替佐米联合来那度胺和地塞米松治疗无即刻自体干细胞移植意向的新诊断多发性骨髓瘤患者（ENDURANCE）：一项多中心、开放标签、3 期、随机、对照临床试验。
Lancet Oncol. 2020 Oct;21(10):1317-1330. doi: 10.1016/S1470-2045(20)30452-6. Epub 2020 Aug 28.
8
The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.细胞遗传学对复发性多发性骨髓瘤患者缓解持续时间和总生存期的影响（BSBMT/UKMF 骨髓瘤 X 复发[强化]的长期随访结果）：一项随机、开放标签、3 期试验。
Br J Haematol. 2019 May;185(3):450-467. doi: 10.1111/bjh.15782. Epub 2019 Feb 6.
9
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.硼替佐米、来那度胺和地塞米松诱导治疗及适应性维持治疗新诊断多发性骨髓瘤的长期随访结果。
J Clin Oncol. 2020 Jun 10;38(17):1928-1937. doi: 10.1200/JCO.19.02515. Epub 2020 Apr 16.
10
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.卡非佐米用于新诊断的多发性骨髓瘤患者的诱导、巩固及维持治疗，伴或不伴自体干细胞移植：随机2期FORTE试验的预设计细胞遗传学亚组分析
Lancet Oncol. 2023 Jan;24(1):64-76. doi: 10.1016/S1470-2045(22)00693-3. Epub 2022 Dec 14.

引用本文的文献

1
Determinants of 15-Year Progression-Free Survival in Multiple Myeloma; Real-World Data From a Single Institution.多发性骨髓瘤15年无进展生存期的决定因素；来自单一机构的真实世界数据
Am J Hematol. 2025 Oct;100(10):1747-1759. doi: 10.1002/ajh.70012. Epub 2025 Jul 18.

本文引用的文献

1
Is There Still a Role for Stem Cell Transplantation in Multiple Myeloma?干细胞移植在多发性骨髓瘤中还有作用吗？
Hematol Oncol Clin North Am. 2024 Apr;38(2):407-420. doi: 10.1016/j.hoc.2023.12.005. Epub 2023 Dec 26.
2
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、硼替佐米、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12.
3
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up.
VRD 方案在多发性骨髓瘤中维持治疗 3 年：总治疗 IIIB 的 15 年随访结果。
Blood Adv. 2024 Feb 13;8(3):703-707. doi: 10.1182/bloodadvances.2023011601.
4
Perspectives on the Treatment of Multiple Myeloma.多发性骨髓瘤的治疗观点。
Oncologist. 2024 Mar 4;29(3):200-212. doi: 10.1093/oncolo/oyad306.
5
Follow up duration of phase III Multiple Myeloma Clinical Trials: A systematic review.III期多发性骨髓瘤临床试验的随访持续时间：一项系统评价。
EJHaem. 2023 Jun 29;4(3):719-722. doi: 10.1002/jha2.680. eCollection 2023 Aug.
6
High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma.多发性骨髓瘤患者在自体干细胞移植前采用大剂量（预处理）方案。
Transplant Cell Ther. 2022 Sep;28(9):572-580. doi: 10.1016/j.jtct.2022.06.013. Epub 2022 Jun 22.
7
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.达雷妥尤单抗、卡非佐米、来那度胺和地塞米松联合最小残留病灶反应适应性治疗新诊断多发性骨髓瘤。
J Clin Oncol. 2022 Sep 1;40(25):2901-2912. doi: 10.1200/JCO.21.01935. Epub 2021 Dec 13.
8
Long-term outcomes after autologous stem cell transplantation for multiple myeloma.自体干细胞移植治疗多发性骨髓瘤的长期疗效。
Blood Adv. 2020 Jan 28;4(2):422-431. doi: 10.1182/bloodadvances.2019000524.
9
Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants.通过在美法仑分次移植中添加硼替佐米和沙利度胺，可以克服不良的中期细胞遗传学情况。
Clin Cancer Res. 2017 Jun 1;23(11):2665-2672. doi: 10.1158/1078-0432.CCR-15-2620. Epub 2016 Nov 3.
10
Curing myeloma at last: defining criteria and providing the evidence.最终治愈骨髓瘤：界定标准并提供证据。
Blood. 2014 Nov 13;124(20):3043-51. doi: 10.1182/blood-2014-07-552059. Epub 2014 Oct 7.